10 results on '"Song, Wantong"'
Search Results
2. Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy.
- Author
-
Liu, Mengrui, Song, Wantong, and Huang, Leaf
- Subjects
- *
DRUG delivery systems , *CANCER immunotherapy , *FIBROBLASTS , *T cells , *TUMOR growth - Abstract
Solid tumors especially desmoplastic tumors are complex organ-like structures. Tumor-associated fibroblasts (TAFs), one type of the stromal cells, support the initiation, progression, and metastasis of carcinomas. TAFs also contribute to immunosuppressive tumor microenvironment (TME) and hinder T lymphocytes in killing tumors. Here, the role of TAFs in TME is discussed. In specific, TAFs form barriers for the penetration of T lymphocytes. TAFs also act as negative regulators for T lymphocytes. These findings suggest that targeting TAFs is a promising strategy for improving cancer immunotherapy. Our previous studies have indicated the ability of therapeutic nanoparticles to distribute into, and deplete or inactivate TAFs. This approach is discussed in the context of developing specific and effective immunotherapies for cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Stable loading and delivery of disulfiram with mPEG-PLGA/PCL mixed nanoparticles for tumor therapy.
- Author
-
Song, Wantong, Tang, Zhaohui, Lei, Tian, Wen, Xue, Wang, Guanyi, Zhang, Dawei, Deng, Mingxiao, Tang, Xing, and Chen, Xuesi
- Subjects
DISULFIRAM ,DRUG delivery systems ,POLYETHYLENE glycol ,POLYLACTIC acid ,GLYCOLIC acid ,NANOMEDICINE ,TUMOR treatment - Abstract
Disulfiram (DSF) showed great potential in an in vitro tumor therapy study; however, those results could not be applied to an in vivo study due to the extreme instability of DSF in blood. Here, we describe a system of methoxy poly(ethylene glycol)- b -poly(lactide- co -glycolide)/poly(ε-caprolactone) (mPEG-PLGA/PCL) mixed nanoparticles (NPs) for DSF loading and delivery. By adjusting the mPEG-PLGA/PCL content ratios, the DSF loading capacity increased to 7.8%, while the hydrodynamic radii of the NPs were around 50-100 nm. The DSF-loaded NPs showed high stability in distilled water and 10% serum-containing phosphate buffered saline. The NPs efficiently protected DSF from degradation while maintaining its anti-tumor properties. Furthermore, a pharmacokinetics study demonstrated that NP delivery system enhanced the DSF concentration in the blood after tail vein injection. Finally, DSF delivery using this model effectively slowed the growth of a 4T1 murine xenograft tumor. From the Clinical Editor The anti-tumor efficacy of the anti-alcoholic drug disulfiram has been known for some time. However, its use in the clinical setting is limited due to the underlying instability of the drug. In this study, the authors utilized a nanocarrier system of mPEG-PLGA/PCL for the delivery of this drug. The promising results may allow encapsulation of other drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. Anti-tumor efficacy of c(RGDfK)-decorated polypeptide-based micelles co-loaded with docetaxel and cisplatin.
- Author
-
Song, Wantong, Tang, Zhaohui, Zhang, Dawei, Zhang, Ying, Yu, Haiyang, Li, Mingqiang, Lv, Shixian, Sun, Hai, Deng, Mingxiao, and Chen, Xuesi
- Subjects
- *
ANTINEOPLASTIC agents , *POLYPEPTIDES , *MICELLES , *DOCETAXEL , *CISPLATIN , *CYCLIC peptides , *DRUG delivery systems - Abstract
Abstract: There are two important obstacles for the currently applied anti-cancer drug delivery systems. One is the conflict between long-circulation and cellular uptake while the other one is the achievement of ideal anti-cancer efficacy. To solve these problems, we designed a polypeptide-based micelle system that combined the advantages of receptor mediated endocytosis and multi-drug delivery. Firstly, an amphiphilic PLG-g-Ve/PEG graft copolymer was prepared by grafting α-tocopherol (Ve) and polyethylene glycol (PEG) to poly(l-glutamic acid) (PLG). Then docetaxel (DTX) and cisplatin (CDDP) were co-loaded into the PLG-g-Ve/PEG micelles via hydrophobic and chelation effect. After that, the surface of the dual-drug-loaded micelles was decorated with an αvβ3 integrin targeting peptide c(RGDfK). The targeted dual-drug-loaded micelles showed synergistic cytotoxicity and enhanced internalization rate in mouse melanoma (B16F1) cells. In vivo tests demonstrated that remarkable long circulation, anti-tumor and anti-metastasis efficacy could be achieved using this drug delivery system. This work revealed a strategy for the design and preparation of anti-cancer drug delivery systems with reduced side effect, enhanced anti-tumor and anti-metastasis efficacy. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
5. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
- Author
-
Lv, Shixian, Li, Mingqiang, Tang, Zhaohui, Song, Wantong, Sun, Hai, Liu, Huaiyu, and Chen, Xuesi
- Subjects
CANCER treatment ,DOXORUBICIN ,POLYPEPTIDES ,NANOMEDICINE ,DRUG delivery systems ,ELECTROSTATIC interaction - Abstract
An amphiphilic anionic copolymer, methoxy poly(ethylene glycol)-b-poly(l-glutamic acid-co-l-phenylalanine) (mPEG-b-P(Glu-co-Phe)), with three functionalized domains, was synthesized and used as a nanovehicle for cationic anticancer drug doxorubicin hydrochloride (DOX·HCl) delivery via electrostatic interactions for cancer treatment. The three domains displayed distinct functions: PEG block chain for prolonged circulation; poly(phenylalanine) domain for stabilizing the nanoparticle construct through hydrophobic/aromatic interactions; and the poly(glutamic acid) domain for providing electrostatic interactions with the cationic drug to be loaded. The copolymer could self-assemble into micellar-type nanoparticles, and DOX was successfully loaded into the interior of nanoparticles by simple mixing of DOX·HCl and the copolymer in the aqueous phase. DOX-loaded mPEG-b-P(Glu-co-Phe) nanoparticles (DOX-NP) had a superior drug-loading content (DLC) (21.7%), a high loading efficiency (almost 98%) and a pH-triggered release of DOX. The size of DOX-NP was ∼140nm, as determined by dynamic light scattering measurements and transmission electron microscopy. In vitro assays showed that DOX-NP exhibited higher cell proliferation inhibition and higher cell uptake in A549 cell lines compared with free DOX·HCl. Maximum tolerated dose (MTD) studies showed that DOX-NP demonstrated an excellent safety profile with a significantly higher MTD (15mg DOX kg
−1 ) than that of free DOX·HCl (5mg DOX kg−1 ). The in vivo studies on the subcutaneous non-small cell lung cancer (A549) xenograft nude mice model confirmed that DOX-NP showed significant antitumor activity and reduced side effects, and then enhanced tumor accumulation as a result of the prolonged circulation in blood and the enhanced permeation and retention effect, compared with free DOX, indicating its great potential for cancer therapy. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
6. Targeting bacterial metabolites in tumor for cancer therapy: An alternative approach for targeting tumor-associated bacteria.
- Author
-
Ji, Guofeng, Zhao, Jingjing, Si, Xinghui, and Song, Wantong
- Subjects
- *
ALTERNATIVE treatment for cancer , *BACTERIAL metabolites , *GUT microbiome , *BACTERIA , *CANCER treatment - Abstract
[Display omitted] Emerging evidence reveal that tumor-associated bacteria (TAB) can facilitate the initiation and progression of multiple types of cancer. Recent work has emphasized the significant role of intestinal microbiota, particularly bacteria, plays in affecting responses to chemo- and immuno-therapies. Hence, it seems feasible to improve cancer treatment outcomes by targeting intestinal bacteria. While considering variable richness of the intestinal microbiota and diverse components among individuals, direct manipulating the gut microbiota is complicated in clinic. Tumor initiation and progression requires the gut microbiota-derived metabolites to contact and reprogram neoplastic cells. Hence, directly targeting tumor-associated bacteria metabolites may have the potential to provide alternative and innovative strategies to bypass the gut microbiota for cancer therapy. As such, there are great opportunities to explore holistic approaches that incorporates TAB-derived metabolites and related metabolic signals modulation for cancer therapy. In this review, we will focus on key opportunistic areas by targeting TAB-derived metabolites and related metabolic signals, but not bacteria itself, for cancer treatment, and elucidate future challenges that need to be addressed in this emerging field. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Recent progress in polymer-based platinum drug delivery systems.
- Author
-
Xiao, Haihua, Yan, Lesan, Dempsey, Elizabeth M., Song, Wantong, Qi, Ruogu, Li, Wenliang, Huang, Yubin, Jing, Xiabin, Zhou, Dongfang, Ding, Jianxun, and Chen, Xuesi
- Subjects
- *
DRUG delivery systems , *POLYMERS , *PLATINUM , *NANOBIOTECHNOLOGY , *CANCER treatment , *ANTINEOPLASTIC agents - Abstract
Graphical abstract Abstract Platinum drugs comprise of almost 50% of all currently used anticancer drugs. They are now widely used in the clinical therapy of various solid tumors, including ovarian, head and neck, colorectal, lung cancers, and so forth. However, their extensive systemic toxicity and the drug resistance acquired by cancer cells limit the applications of platinum drugs. Modern nanobiotechnology provides the possibility for targeted delivery of platinum drugs to the tumor site, thereby minimizing toxicity and optimizing the efficacies of the drugs. Numerous drug delivery carriers, such as polymer nanoparticles, solid lipids, and inorganic nanoparticles, have been developed over the years for delivering platinum drugs. Thus, significant improvements have been made in this field, especially for polymer-based platinum drug delivery systems. In the past five years, particularly interesting studies have been done regarding polymer-based carriers for platinum(IV) drugs, which are chemically inert but can be activated either by intracellular glutathione (GSH) and ascorbic acid (chemically reductive platinum(IV) drugs) or by ultraviolet (UV)/green light (photosensitive platinum(IV) drugs). This review presents a comprehensive overview on the development of various types of polymer-based platinum drug delivery systems. It spans both single-drug carriers and carriers that are combined with other imaging agents, drug sensitizers, and anticancer drugs. Their fabrication methods, mechanisms of action, their applications in cancer therapy, as well as the prospect of their development in the future are also predicted. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. Well-defined polymer-drug conjugate engineered with redox and pH-sensitive release mechanism for efficient delivery of paclitaxel.
- Author
-
Lv, Shixian, Tang, Zhaohui, Zhang, Dawei, Song, Wantong, Li, Mingqiang, Lin, Jian, Liu, Huaiyu, and Chen, Xuesi
- Subjects
- *
CONJUGATED polymers , *NANOMEDICAL research , *CANCER treatment , *DISULFIDES , *ESTERS , *PACLITAXEL , *OXIDATION-reduction reaction , *HYDROGEN-ion concentration - Abstract
The synthesis of polymer–drug conjugate (PDC) capable of convenient preparation and controlled release of therapeutic agents is still an urgent requirement in drug delivery field. Herein, we develop a novel anti-cancer PDC engineered with side groups of disulfide and ester bonds for on-demand delivery of paclitaxel (PTX) with redox and pH dual sensitive behaviors. A simple polymer, 3,3′-dithiodipropionic acid functionalized poly(ethylene glycol)- b -poly( l -lysine) (mPEG- b -P(LL-DTPA)), was synthesized and PTX was directly conjugated to the carboxyl groups of mPEG- b -P(LL-DTPA) to obtain the disulfide-containing polymer–PTX conjugate (P(L-SS-PTX)). Another structural similar polymer–PTX conjugate without disulfide bonds (P(L-PTX)) was also prepared to verify the function of disulfide linkages. The P(L-SS-PTX) micelles showed rapid drug release under tumor-relevant reductive conditions as designed. Interestingly, the PTX release from P(L-SS-PTX) micelles could also be promoted by the increased acidity (pH ≈ 5). In vitro cytotoxicity study showed that the P(L-SS-PTX) micelles exhibited significantly enhanced cytotoxicity against a variety of tumor cells compared to the non-sensitive P(L-PTX) micelles. The in vivo studies on B16F1 melanoma bearing C57BL/6 mice demonstrated the superior antitumor activity of P(L-SS-PTX) over both free PTX and P(L-PTX). This dual-sensitive prodrug provides a useful strategy for anti-tumor drug delivery. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Cisplatin crosslinked pH-sensitive nanoparticles for efficient delivery of doxorubicin.
- Author
-
Li, Mingqiang, Tang, Zhaohui, Lv, Shixian, Song, Wantong, Hong, Hua, Jing, Xiabin, Zhang, Yuanyuan, and Chen, Xuesi
- Subjects
- *
CISPLATIN , *NANOMEDICINE , *DRUG delivery systems , *DOXORUBICIN , *POLYSACCHARIDES , *SUCCINIC acid - Abstract
Abstract: pH responsive cisplatin prodrug crosslinked polysaccharide-based nanoparticles were developed from succinic acid decorated dextran (Dex-SA) for active loading and triggered intracellular release of doxorubicin (DOX). Nanoparticles with uniform size were formed spontaneously in aqueous medium via electrostatic interaction between anionic Dex-SA and cationic DOX, and subsequently transformed into crosslinked nanoparticles (CL-Nanoparticles) in situ by readily crosslinking the micelles via chelate interactions between the ionic polymeric carrier and the platinum (II) antitumor drug. This strategy eliminated the need of organic solvents and sophisticated processes in the drug loading procedure. The in vitro release studies showed that DOX was released from the CL-Nanoparticles in a controlled and pH-dependent manner. Furthermore, the pharmacokinetics and biodistribution investigations indicated that, as compared to the non-crosslinked nanoparticles (NCL-Nanoparticles) and free DOX, the CL-Nanoparticles significantly prolonged the blood circulation time of drug, decreased accumulation in the normal tissues and enriched drug into the tumors. As a consequence, the DOX-loaded CL-Nanoparticles exhibited enhanced therapeutic efficacy in tumor-bearing mice compared with the NCL-Nanoparticles and free DOX, which were further confirmed by the histological and immunohistochemical analyses. These cisplatin prodrug crosslinked polysaccharide nanoparticles proved to be a promising nanomedicine drug delivery system for tumor-targeted delivery of DOX. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
10. Traditional herbal medicine and nanomedicine: Converging disciplines to improve therapeutic efficacy and human health.
- Author
-
Zhang, Jing, Hu, Kaili, Di, Liuqing, Wang, Penglong, Liu, Zhidong, Zhang, Jinming, Yue, Pengfei, Song, Wantong, Zhang, Jingwei, Chen, Tongkai, Wang, Zuhua, Zhang, Yongtai, Wang, Xiaoying, Zhan, Changyou, Cheng, Yung-Chi, Li, Xiang, Li, Quan, Fan, Jing-Yu, Shen, Youqing, and Han, Jing-Yan
- Subjects
- *
HERBAL medicine , *TRADITIONAL medicine , *NANOMEDICINE , *TREATMENT effectiveness , *DIAGNOSIS - Abstract
[Display omitted] Traditional herbal medicine (THM), an ancient science, is a gift from nature. For thousands of years, it has helped humans fight diseases and protect life, health, and reproduction. Nanomedicine, a newer discipline has evolved from exploitation of the unique nanoscale morphology and is widely used in diagnosis, imaging, drug delivery, and other biomedical fields. Although THM and nanomedicine differ greatly in time span and discipline dimensions, they are closely related and are even evolving toward integration and convergence. This review begins with the history and latest research progress of THM and nanomedicine, expounding their respective developmental trajectory. It then discusses the overlapping connectivity and relevance of the two fields, including nanoaggregates generated in herbal medicine decoctions, the application of nanotechnology in the delivery and treatment of natural active ingredients, and the influence of physiological regulatory capability of THM on the in vivo fate of nanoparticles. Finally, future development trends, challenges, and research directions are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.